Trial · NCT00448409
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
NCT00448409, Phase 2, Completed, The Methodist Hospital Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer. Trials, record NCT00448409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00448409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
- NCT number
- NCT00448409
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- The Methodist Hospital Research Institute
- Conditions
- Prostatic Neoplasms
- Interventions
- TroVax, GM-CSF
- First posted
- 2007-03-16
- Last updated
- 2016-03-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PSA response rate to TroVax® and TroVax® in combination with GM-CSF | restaging every 8 weeks | |
| Primary | Anti-5T4 antibody levels | 1st 2 cycles every 2 wks; thereafter about every 4 wks | |
| Primary | CD8+ve cellular response to 5T4 antigen as measured by Elispot | at end of study | |
| Primary | Assessment of the number of adverse events and serious adverse events in both groups | AEs as occur | |
| Secondary | Objective response rate | restaging every 8 weeks | |
| Secondary | Overall survival of the patients | restaging every 8 weeks | |
| Secondary | Progression-free survival | restaging every 8 weeks | |
| Secondary | Time to progression | restaging every 8 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00448409
GET https://conductscience.org/api/trials/v1/NCT00448409/registered